Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Questions and Answers from the Symposium Strategies for Success in Intrathecal Pain Management

Compass Points

Premiere Date: Tuesday, May 20, 2014

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, May 20, 2015
Note: Credit Is No Longer Available

Faculty

David L. Caraway, MD, PhD  Medical Director Center for Pain Relief Tri State, PLLC Huntington, WV

Statement of Need

Optimal pain management is a national health care priority, and this field of medicine has come a long way in improving the safe and effective use of opioid therapy for patients with both acute and chronic pain. For many patients with severe and intractable chronic pain, oral opioid therapy is not enough; other options are better suited to achieving pain control. One such option is intrathecal (IT) therapy, which is becoming an increasingly accepted strategy for using opioid and non-opioid analgesics for the management of intractable pain in appropriately selected patients.

A symposium at a national pain meeting held March 7, 2014, provided participants with evidence and insights to help them apply personalized medicine and evidence-based patient-selection criteria for IT pain management, integrate trialing, and individualize the titration schedule for each patient starting IT therapy. This Compass Points reflects the questions that were asked at the symposium and addressed in an Expert Interview with Dr. Caraway.

The entire symposium can be viewed at http://www.cmeoutfitters.com/cmea.asp?ID=890

Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15(5):483-495; discussion 496. PMID: 22494332.

Activity Goal

Apply best-practice evidence for intrathecal drug delivery for the management of chronic, intractable pain.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply evidence-based, best-practice criteria to decision-making and individualized treatment-planning when considering and initiating intrathecal drug delivery for pain management.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Pain specialists, physicians, physician assistants, and other health care professionals with an interest in pain medicine.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST894 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Caraway has disclosed that he has received research and grant support from Jazz Pharmaceuticals, Inc. and Medtronic, Inc. He is on the speakers bureau of Jazz Pharmaceuticals, Inc. and Medtronic, Inc. He serves as a consultant for Jazz Pharmaceuticals, Inc. and Medtronic, Inc.

Tony Graham, MD (peer reviewer) has nothing to disclose.

Robert Kennedy (planning committee) has nothing to disclose.

Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.

Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.

CME Outfitters, LLC, the faculty, and Jazz Pharmaceuticals, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).